With Genentech' s collaborations with IMGN and SGEN, what does it need this position for?
Group Leader- Antibody-Drug Conjugation (ADC).
A Senior Scientist/Associate Director position is available for a highly motivated and innovative scientist with strong leadership and collaborative skills to join our antibody drug conjugation (ADC) program. Candidates should have extensive experience in protein and antibody conjugations and be a demonstrated thought leader in the ADC field so that they will be able to make immediate contributions to a vibrant and productive program undergoing expansion at this time. The successful candidate will interface with both chemist and biologist in developing new technologies for the production of ADCs as well as optimizing current strategies. The position allows the successful candidate to play a pivotal role in augmenting Genentech’s strong clinical pipeline of new therapeutic ADC candidates.
DNA is developing their own ADC drugs now. That's one (of many) reasons why IMGN needs new leadership that can move the early pipeline molecules forward on a more timely basis. Competition is increasing; there are likely many other small, private ADC co's that we don't even know about. IMGN needs to get their rears in gear.
The positive is that Genentech is showing that ADCs are really the way to go. IMGN has to do more tie ups with small and big companies with unique antibodies. I'll take the 10-20% royalty anytime just to expand the portfolio. I wonder if ADCs can be employed for HIV, to kill T cells expressing the entry receptors. Sangamo definitely believes that depleting cells expressing CCR5, using their meganuclease, can decrease HIV titers. There are probably antibodies out there to CCR5 that are ready for ADC conjugation. I don't know if CCR5 gets internalized though.
The problem with IMGN, probably, is that they have not been very good, or very lucky, at picking good target antigens, or antibodies, or indications to pursue. It does take a lot of luck, aside from being good at science.